Circulating free DNA as a predictive biomarker for response to nivolumab and platinum-based chemotherapy in metastatic esophageal adenocarcinoma: a prospective pilot study
Early cfDNA kinetics-particularly a Day 30/Baseline ratio <0.4-strongly predicted response and survival in mEAC patients receiving chemoimmunotherapy. cfDNA monitoring offers a promising non-invasive tool for early treatment stratification and response assessment in this population.
Authors
- Qianqian Du (ORCID: https://orcid.org/0000-0002-5948-739X)
- Bo Fan (ORCID: https://orcid.org/0000-0001-9577-8592)
Institutions
- Shandong Provincial Hospital (CN)
- Shandong Provincial QianFoShan Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-03
- DOI
- https://doi.org/10.3389/fonc.2025.1678068
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00